PHARMACOLOGY EXAM
QUESTIONS AND ANSWERS WITH
RATIONALE 2026/2027
110 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
PHARMACOLOGY EXAM QUESTIONS AND ANSWERS WITH RATIONALE 2026/2027. It contains 110
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 110 Questions
Foundations - Application - Pharmacology AND WITH Rationale 2026/2027 Pharmacology Graduate /
Advanced Undergraduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pharmacological Therapies 1-19 Medication, Explains, Effect, Mechanism, Likely
Reduction OF RISK Potential 20-38 Likely, Antagonist, Appropriate, Interaction, Cyp3a4
Physiological Adaptation 39-57 Effect, Opioid, Develops, Explains, Mechanism
Basic CARE AND Comfort 58-76 Mechanism, Phenytoin, Renal, Severe, Hypertension
Safety AND Infection Control 77-95 Prescribed, Likely, Severe, Parameter, P-glycoprotein
Health Promotion AND 96-110 Receiving, Steady-state Concentration, Treated, Effect,
Maintenance Hypertension
TOTAL 110 All questions include answers and detailed rationales
,Section A - Pharmacological Therapies
Q1.
In a phase I trial, a novel drug exhibits a volume of distribution of 0.5 L/kg and a half-life of
24 hours. If the drug is administered as an IV loading dose and then continuous infusion,
which pharmacokinetic parameter is most critical for determining the infusion rate to
maintain steady-state concentration?
A. Clearance B. Volume of distribution
C. Half-life D. Bioavailability
Correct: A - Clearance
Rationale:At steady state, the infusion rate equals clearance times target concentration
(Css). Clearance is the primary determinant of the maintenance dose rate. Volume of
distribution affects loading dose, half-life influences time to steady state, and bioavailability is
irrelevant for IV administration.
Why the other answers are wrong:
B. Volume of distribution determines the loading dose, not the infusion rate.
C. Half-life affects time to reach steady state but not the infusion rate itself.
D. Bioavailability is 100% for IV drugs and does not affect infusion rate.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4: Pharmacokinetics.
Q2.
A drug is a weak acid with a pKa of 4.4. In a patient with metabolic alkalosis (urine pH 8.0),
how does the urinary excretion of this drug compare to a patient with acidic urine (pH
5.0)?
A. Excretion is decreased because more B. Excretion is increased because more
drug is in the ionized form. drug is in the ionized form.
C. Excretion is decreased because more D. Excretion is unchanged because pKa and
drug is in the non-ionized form. urine pH are unrelated.
Correct: B - Excretion is increased because more drug is in the ionized form.
Rationale:For a weak acid, alkaline urine favors ionization (A-), which traps the drug in the
renal tubule, preventing reabsorption and increasing excretion. In acidic urine, the drug is
non-ionized and is reabsorbed, decreasing excretion.
Why the other answers are wrong:
A. This is the opposite; alkaline urine increases ionized fraction and excretion.
C. Alkaline urine decreases non-ionized fraction, not increases.
D. Urine pH significantly affects excretion of weak acids and bases.
Page 3
, Section A - Pharmacological Therapies
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5: Drug Elimination.
Q3.
A patient on a stable dose of warfarin is started on a new medication. Three weeks later,
their INR drops from 2.5 to 1.8. Which mechanism most likely explains this interaction?
A. The new drug inhibits CYP2C9, B. The new drug induces CYP2C9,
decreasing warfarin metabolism. increasing warfarin metabolism.
C. The new drug displaces warfarin from D. The new drug reduces vitamin K
plasma protein binding sites. absorption from the gut.
Correct: B - The new drug induces CYP2C9, increasing warfarin metabolism.
Rationale:CYP2C9 induction increases warfarin metabolism, reducing its anticoagulant effect
and INR. Inhibition would raise INR, displacement is transient and not clinically significant,
and reduced vitamin K absorption would increase INR.
Why the other answers are wrong:
A. Inhibition of CYP2C9 would increase warfarin levels and INR, not decrease.
C. Protein binding displacement transiently increases free drug but is not the cause of a
sustained INR drop.
D. Reduced vitamin K absorption would increase INR, not decrease.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 9: Drug Interactions.
Q4.
Which combination of receptor activity best describes the mechanism of action of a drug
used to treat opioid-induced constipation that does NOT cross the blood-brain barrier?
A. Peripheral mu-opioid antagonist B. Central mu-opioid agonist
C. Peripheral delta-opioid agonist D. Central kappa-opioid antagonist
Correct: A - Peripheral mu-opioid antagonist
Rationale:Drugs like methylnaltrexone are peripherally acting mu-opioid antagonists that
block opioid effects in the gut, relieving constipation without reversing central analgesia.
Central actions would negate the analgesic benefit.
Why the other answers are wrong:
B. A central agonist would worsen constipation.
C. Delta-opioid agonists are not used for constipation.
D. Central kappa antagonism is not relevant to opioid-induced constipation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13: Opioid Analgesics.
Page 4
QUESTIONS AND ANSWERS WITH
RATIONALE 2026/2027
110 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
PHARMACOLOGY EXAM QUESTIONS AND ANSWERS WITH RATIONALE 2026/2027. It contains 110
carefully selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 110 Questions
Foundations - Application - Pharmacology AND WITH Rationale 2026/2027 Pharmacology Graduate /
Advanced Undergraduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pharmacological Therapies 1-19 Medication, Explains, Effect, Mechanism, Likely
Reduction OF RISK Potential 20-38 Likely, Antagonist, Appropriate, Interaction, Cyp3a4
Physiological Adaptation 39-57 Effect, Opioid, Develops, Explains, Mechanism
Basic CARE AND Comfort 58-76 Mechanism, Phenytoin, Renal, Severe, Hypertension
Safety AND Infection Control 77-95 Prescribed, Likely, Severe, Parameter, P-glycoprotein
Health Promotion AND 96-110 Receiving, Steady-state Concentration, Treated, Effect,
Maintenance Hypertension
TOTAL 110 All questions include answers and detailed rationales
,Section A - Pharmacological Therapies
Q1.
In a phase I trial, a novel drug exhibits a volume of distribution of 0.5 L/kg and a half-life of
24 hours. If the drug is administered as an IV loading dose and then continuous infusion,
which pharmacokinetic parameter is most critical for determining the infusion rate to
maintain steady-state concentration?
A. Clearance B. Volume of distribution
C. Half-life D. Bioavailability
Correct: A - Clearance
Rationale:At steady state, the infusion rate equals clearance times target concentration
(Css). Clearance is the primary determinant of the maintenance dose rate. Volume of
distribution affects loading dose, half-life influences time to steady state, and bioavailability is
irrelevant for IV administration.
Why the other answers are wrong:
B. Volume of distribution determines the loading dose, not the infusion rate.
C. Half-life affects time to reach steady state but not the infusion rate itself.
D. Bioavailability is 100% for IV drugs and does not affect infusion rate.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4: Pharmacokinetics.
Q2.
A drug is a weak acid with a pKa of 4.4. In a patient with metabolic alkalosis (urine pH 8.0),
how does the urinary excretion of this drug compare to a patient with acidic urine (pH
5.0)?
A. Excretion is decreased because more B. Excretion is increased because more
drug is in the ionized form. drug is in the ionized form.
C. Excretion is decreased because more D. Excretion is unchanged because pKa and
drug is in the non-ionized form. urine pH are unrelated.
Correct: B - Excretion is increased because more drug is in the ionized form.
Rationale:For a weak acid, alkaline urine favors ionization (A-), which traps the drug in the
renal tubule, preventing reabsorption and increasing excretion. In acidic urine, the drug is
non-ionized and is reabsorbed, decreasing excretion.
Why the other answers are wrong:
A. This is the opposite; alkaline urine increases ionized fraction and excretion.
C. Alkaline urine decreases non-ionized fraction, not increases.
D. Urine pH significantly affects excretion of weak acids and bases.
Page 3
, Section A - Pharmacological Therapies
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5: Drug Elimination.
Q3.
A patient on a stable dose of warfarin is started on a new medication. Three weeks later,
their INR drops from 2.5 to 1.8. Which mechanism most likely explains this interaction?
A. The new drug inhibits CYP2C9, B. The new drug induces CYP2C9,
decreasing warfarin metabolism. increasing warfarin metabolism.
C. The new drug displaces warfarin from D. The new drug reduces vitamin K
plasma protein binding sites. absorption from the gut.
Correct: B - The new drug induces CYP2C9, increasing warfarin metabolism.
Rationale:CYP2C9 induction increases warfarin metabolism, reducing its anticoagulant effect
and INR. Inhibition would raise INR, displacement is transient and not clinically significant,
and reduced vitamin K absorption would increase INR.
Why the other answers are wrong:
A. Inhibition of CYP2C9 would increase warfarin levels and INR, not decrease.
C. Protein binding displacement transiently increases free drug but is not the cause of a
sustained INR drop.
D. Reduced vitamin K absorption would increase INR, not decrease.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 9: Drug Interactions.
Q4.
Which combination of receptor activity best describes the mechanism of action of a drug
used to treat opioid-induced constipation that does NOT cross the blood-brain barrier?
A. Peripheral mu-opioid antagonist B. Central mu-opioid agonist
C. Peripheral delta-opioid agonist D. Central kappa-opioid antagonist
Correct: A - Peripheral mu-opioid antagonist
Rationale:Drugs like methylnaltrexone are peripherally acting mu-opioid antagonists that
block opioid effects in the gut, relieving constipation without reversing central analgesia.
Central actions would negate the analgesic benefit.
Why the other answers are wrong:
B. A central agonist would worsen constipation.
C. Delta-opioid agonists are not used for constipation.
D. Central kappa antagonism is not relevant to opioid-induced constipation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 13: Opioid Analgesics.
Page 4
